Skip to content

No results found

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

HUMA Humacyte, Inc. Common Stock
$0.57 -14.73% -0.10
Notify me if price changes either direction
Interactive Brokers Logotype

Buy HUMA stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 125.6M
Enterprise value 140.5M
Trailing PE -0.45722222222222
Forward PE -6.4342856
PEG Ratio 0.0068583333333333
Enterprise to EBITDA -1.395
Enterprise to revenue 68.96
Price to book MRQ 39.741173
Price to sales TTM 72.26617

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 2.0M
EBITDA -100727672
Diluted EPS TTM -0.26
Total Cash (MRQ) 50.5M
Current ratio (MRQ) 3.69
Operating Cash Flow (TTM) -96537000

HUMA trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months
Home

No results found

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.